Allergy Therapeutics PLC
LSE:AGY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Allergy Therapeutics PLC
Cash from Investing Activities
Allergy Therapeutics PLC
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Cash from Investing Activities
-£4.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-4%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Investing Activities
-£4.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Investing Activities
-$6.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-89%
|
CAGR 10-Years
-5%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Investing Activities
-$388m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
|
Animalcare Group PLC
LSE:ANCR
|
Cash from Investing Activities
-£62.5m
|
CAGR 3-Years
-179%
|
CAGR 5-Years
-98%
|
CAGR 10-Years
-55%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Cash from Investing Activities
£2.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Allergy Therapeutics PLC
Glance View
Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.
See Also
What is Allergy Therapeutics PLC's Cash from Investing Activities?
Cash from Investing Activities
-4.2m
GBP
Based on the financial report for Dec 31, 2025, Allergy Therapeutics PLC's Cash from Investing Activities amounts to -4.2m GBP.
What is Allergy Therapeutics PLC's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-4%
Over the last year, the Cash from Investing Activities growth was -416%. The average annual Cash from Investing Activities growth rates for Allergy Therapeutics PLC have been 3% over the past three years , -13% over the past five years , and -4% over the past ten years .
